Share these results with your doctor to see if your symptoms may be associated with chronic dry eye
Below is a summary of your Xiidra.com quiz responses that you can share with a doctor to help guide your discussion about your dry eye symptoms.
The dry symptoms that bother me are when my eyes feel .
I experience my dry eye symptoms .
I am currently treating my dry eyes with .
My dry eye symptoms bother me .
, I am interested in talking to my doctor about a prescription treatment that may
provide symptom relief.
1. Why am I not getting lasting relief?
2. How does Xiidra work differently?
3. Is inflammation part of my dry eye diagnosis?
4. Is Xiidra right for me?
Mention all prescription medicines, over-the-counter medicines, vitamins, and herbal supplements. Also tell your doctor about any other medications for chronic dry eye you've taken in the past.
Xiidra (lifitegrast ophthalmic solution) 5% is a prescription eye drop used to treat the signs and symptoms of dry eye disease.
Do not use Xiidra if you are allergic to any of its ingredients. Seek medical care immediately if you get any symptoms of an allergic reaction.
The most common side effects of Xiidra include eye irritation, discomfort or blurred vision when the drops are applied to the eyes, and an unusual taste sensation.
For additional Important Safety Information, see next page.
Discuss Xiidra as a treatment option with your doctor. Here's why:
It may offer lasting relief of symptoms in as little as 2 weeks for some patients with continued twice-daily use*
It specifically targets a source of inflammation that can cause chronic dry eye
As many as 1,500,000 people† have been prescribed Xiidra.
Good news! 90% of patients using a Xiidra Savings Card paid $0 for their prescription!‡ If you have commercial prescription insurance, you may pay $0 for a 90-day prescription of Xiidra, including refills!§
Get your savings card at xiidra.copaysavingsprogram.com
Xiidra is now covered for approx 70% of patients with Medicare prescription coverage.||
*Xiidra may provide lasting symptom relief for some patients with continued twice-daily use. In clinical studies, Xiidra reduced symptoms of eye dryness at 2 weeks in 2 out of 4 studies, with improvements observed at 6 and 12 weeks in all 4 studies.
†Based on an analysis of IQVIA LRx claims data from July 2016 to January 2024.
‡Data on file. ConnectiveRx Xiidra Savings Card Co-pay. Average payments between Jan 1. 2023 – Dec. 6, 2023.
§Limitations apply. Eligible, commercially insured patients using the Xiidra Savings Card pay $0 for their first prescription of Xiidra. $0 first fill available for prescriptions up to 90 days. After the first fill, eligible, commercially insured patients may pay as little as $0 for prescriptions of Xiidra. The copay card can be used once every 21 days for 30-day fill and 63 days for 90-day fill. This offer is not valid for patients whose prescriptions are reimbursed by any federal or state healthcare program, including Medicaid, Medicare, TRICARE, or any other federal or state healthcare program. Bausch + Lomb reserves the right to rescind, revoke, or amend this program without notice. See complete Terms & Conditions for details.
∥Based on data from February 2024.
Important Safety Information (cont)
To help avoid eye injury or contamination of the solution, do not touch the container tip to your eye or any surface. If you wear contact lenses, remove them before using Xiidra and wait for at least 15 minutes before placing them back in your eyes.
It is not known if Xiidra is safe and effective in children under 17 years of age.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch,
or call 1-800-FDA-1088.
For additional safety information, please see Full Prescribing Information and Patient Information at Xiidra.com and discuss with your doctor.
XIIDRA, the XIIDRA logo and ii are registered trademarks of Bausch + Lomb.
©2025 Bausch + Lomb. XDR.0031.USA.24 (v2)
All information and materials on this site pertain to the U.S. only, unless otherwise indicated.